uniQure N.V. (NASDAQ:QURE) is one of the stocks Jim Cramer recently talked about. A caller asked whether to buy, hold, or take profits in the stock after the release of clinical data, which indicated its gene therapy candidate significantly slowed the progression of Huntington’s disease. Cramer said: “Yeah, I saw that news and it was really terrific. But I also saw that an insider sold about $9 million worth of stock after the run. I think that’s a, it’s a parabola, and after a parabolic move, I will not ...

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. uniQure N.V. is one of them. uniQure N.V. (NASDAQ:QURE) is a leading gene therapy company focused on developing transformative treatments for severe medical conditions. Its pipeline includes HEMGENIX for hemophilia B and AMT-130, a gene therapy candidate for Huntington’s disease, which has recently attracted significant attention. In late September 2025, uniQure N.V. (NASDAQ:QURE) announced positive topline results ...